Von Harald R. Dörr, Hermann Keuper

Durch die Fusion der Diagnostikfirmen Dade und Behring im Jahre 1997 ergab sich die Situation, dass an zwei Standorten Reagenzien für die Gerinnungsdiagnostik produziert wurden. Zur Kosteneinsparung und Effizienzsteigerung wurde beschlossen, die Produktionsaktivitäten des Standorts Miami, USA, nach Marburg, Deutschland, zu verlegen. In einem 18-monatigen Projekt wurden Produktionsanlagen und -prozesse sowie unterstützende Funktionen so transferiert, dass es bei weiterhin laufendem Absatz nicht zu einem Lieferabriss kam. In dem folgenden Artikel wird das Umfeld des Produktionstransfers beschrieben und dargestellt, welche Aufgaben zu lösen waren und wie das Projekt strukturiert und ausgeführt wurde.

1 Introduction

In October 1997, Dade International (Deerfield, IL) and the Behring Diagnostics unit of Hoechst AG (Frankfurt, Germany) completed their merger by forming a new company called Dade Behring, Inc.

The company is headquartered in Deerfi eld, Illinois, with a branch offi ce in Frankfurt, has approximately 8,700 employees through out the world, operations across the industrialised nations, and the broadest available offering of products and services for clinical laboratories in hospitals and elsewhere. With leadership positions in areas such as chemistry/immunochemistry, Hemostasis/ coagulation, microbiology, plasma-protein analysis, cardiac diagnostics, drug monitoring, and quality assurance, approximately half of Dade Behring’s annual sales of 1.3 billion USD are in the United States and half in other countries worldwide.

Dade International as well as Behring Diagnostics were strong in the field of Hemostasis with reagent manufacturing sites in Miami, Florida, USA and Marburg, Germany. Hemostasis analysers and reagents are used in testing the ability of a patient’s blood to form and dissolve clots. After a thorough investigation the company decided to close the Miami plant and consolidate all manufacturing activities for Hemostasis reagents to the Marburg site.

Both companies had an overlapping product portfolio (reagents and instruments). Parallel to the operations transfer two other major projects (cross application, customer conversion) were launched in order to consolidate the portfolio, thus minimising the number of products to be transferred. The objectives were to run Behring reagents on Dade Instruments and vice versa (application) and then to convert customer to the new combined portfolio. At the same time, the company decided to consolidate warehouses which resulted in major inventory moves.


... Weiterlesen in PDF-Ausgabe (Für registrierte GPM-Mitglieder)

---> Zum Inhaltsverzeichnis von PMaktuell - Heft 3/2000